Open randomized intergroup trial about efficacy and the safety of minodronate raloxifene and eldecalcitol in the drug choice after teriparatide 24 months administration for osteoporosis.

Open randomized intergroup trial about efficacy and the safety of minodronate raloxifene and eldecalcitol in the drug choice after teriparatide 24 months administration for osteoporosis. - Controlled trial about the osteoporotic therapeutic drug choice after the teriparatide 24 months administration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010413

Enrollment

150

Registered

2013-04-03

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Minodronate administration for 48 weeks. 50mg once /4 week Raloxifene administration for 48 weeks. 60mg once /1 day Eldecalcitol administration for 48 weeks. 0.75 once /1 day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women who had teriparatide administration for 24 months with the criteria for initiating treatment to prevent fragility fractures, which were based on the Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2006 edition). Accepted informed consent.

Exclusion criteria

Exclusion criteria: The patients who do not come to the hospital. The patients who cancele an agreement. The patients who discontinue osteoporosis medicine. The patients who have a fracture on the course. The patients that doctor attending judge cancellation of study.

Design outcomes

Primary

Measure	Time frame
The change of bone mineral density in the 24th and the 48th week after medication change. The change of the bone biochemical markers in the 12th, 24th, 36th and 48th week after medication change. The occurrence of fracture and adverse event.	—

Countries

Japan

Contacts

Public ContactShinichi Nakatoh

Asahi General Hospital Orthopedics

nakato38@cosmo21.net0765-83-1160

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026